Grand Pack Machinery Launches The Newest Pharmatical Filling Machine At ALLPACK INDONESIA EXPO

Grand Pack Machinery, INC. announces the debut of its latest innovation, the GGS Pharmaceutical Filling Machines, in the 23rd ALLPACK INDONESIA. Designed for the food and pharmaceutical industries, this highly customizable series has streamlined structures and is fitted with casters, which makes it convenient to move them and help customers save costs.

It took us five years to develop the filling machines. Only after dozens of prototype testing and modifications are we ready to debut them in this exhibition. With the features of cost-effectiveness and high filling accuracy, our innovations can meet the production needs of customers in the pharmaceutical and food industries. ” said Bruce Fu, CEO of Grand Pack.

Features:

The GGS series is comprised of four models, namely 118-P5, 240-P5, 240-P10, 240-P15, all of which are constructed in strict accordance with GMP standards. To boost their filling performance, we have mounted pump control panels on them, which makes it possible to real-time monitor the filling speed and increases the level of automation.

Grand’s latest GGS pharmaceutical liquid filling machine

Exploring the Indonesia Market:

As Indonesia’s population expands to 400 million, and the economy becomes one of the fastest-growing in the world, we have established our branch Trustar in this country. As such, by attending this year’s exhibition, we aim to establish our identity in the overseas market, and promote our branch.

In addition, we will also debut our other pharmaceutical filling solutions dedicated to sustainable development at the ALLPack Expo. For example, we are the first to produce a small version of BFS machines that traditionally occupy large footprints. Such upgrade help customers save much space, and reduce waste and cost.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version